A new approach to support specialist prescribing of bDMARDs
Arthritis Australia is part of an eight-member Consortium led by NPS MedicineWise, which is the successful recipient of the ‘Value in Prescribing biological disease-modifying anti-rheumatic drugs (bDMARDs)’ government grant.
The grant will fund a project to improve the use of bDMARDs to ensure the best health and economic outcomes from investment in these therapies.
Australian Rheumatology Association and Arthritis Australia Statement regarding the use of glucosamine for the treatment of Osteoarthritis
Recent media reports have raised concern over the use of glucosamine in the treatment of osteoarthritis. These reports appear to be based on two unrelated...
PIDA Accessible Packaging Design Special Award 2019
Ecolean received the GOLD award for the Accessible Packaging Design Special Award 2020. Congratulations to Ecolean for their innovative flexible pouch, and to Bannister Downs...
Reducing opioid harm through regulatory changes – Information for consumers, patients and carers
The Australian Government, through the Therapeutic Goods Administration (TGA) within the Department of Health, is implementing a number of regulatory changes in order to minimise...
Sign up to Arthritis Insights
Regular updates, news and research findings delivered to your inbox: